| HOME >> MEDICINE >> TECHNOLOGY |
Position emission tomography (PET) scans were performed before the surgery and repeated six months later and then again one year after the surgery. The motor network on the untreated side of the body got worse, and the treated side got better. The level of improvements in the motor network correlated with increased clinical ratings of patient disability, added Dr. Feigin.
"Having this information from a PET scan allows us to know that what we are seeing is real," Dr. Eidelberg added. The scans also detected differences in responses between dose groups, with the highest gene therapy dose demonstrating a longer-lasting effect. "This study demonstrates that PET scanning can be a valuable marker in testing novel therapies for Parkinson's disease," he said.
The gene therapy technique was developed by Neurologix Inc., a New Jersey-based company. Scientists are now working on a design for a phase 2 blinded study that would include a larger number of patients to test the effectiveness of the treatment.
About The Feinstein Institute for Medical Research
The Feinstein Institute for Medical Research is home to international
scientific leaders in Parkinson's disease, Alzheimer's, psychiatric
disorders, rheumatoid arthritis, lupus, sepsis, inflammatory bowel disease,
diabetes, human genetics, leukemia, lymphoma, neuroimmunology, and
medicinal chemistry. Part of the North Shore-LIJ Health System, FIMR ranks
in the top 6th percentile of all National Institutes of Health grants
awarded to research centers. Feinstein researchers are developing new drugs
and drug targets, and producing results where science meets the patient.
For more information, please visit
| SOURCE The Feinstein Institute for Medical Research Copyright©2007 PR Newswire. All rights reserved |